Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Minor bleeding ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding ‐ not reported · people with cancer with VTE receiving secondary prophylaxis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with different dose of the same anticoagulant (low certainty).
1 finding from 1 review
Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with antiplatelet agent (low certainty).
1 finding from 1 review
Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events (minor bleeding) · people hospitalised with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (minor bleeding) · people hospitalised with COVID‐19
Higher‐dose anticoagulants leads to higher adverse events (minor bleeding) compared with lower‐dose anticoagulants (high certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in minor bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes minor bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in minor bleeding (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
Number of participants with minor procedure‐related bleeding within 7 days of surgery · people with abnormal coagulation requiring a central venous catheter
It is very uncertain whether comparison of plasma transfusions changes minor procedure‐related bleeding compared with no plasma transfusions when the INR is 1.5 prior to central venous… (very low certainty).
1 finding from 1 review
Minor bleeding · patients with venous thromboembolism.
It is very uncertain whether 10 mg warfarin nomogram changes minor bleeding it is not major bleeding compared with 5 mg warfarin nomogram (very low certainty).
1 finding from 1 review